TheraRadar
Clinical-Stage Companies / Kythera Biopharmaceuticals

Kythera Biopharmaceuticals

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 4/1/2014

18
Total Trials
9
Phase 3
3
Phase 2
0
Recruiting
177
Score

Pipeline by Phase

Phase 3
9
Phase 2
3
Phase 1
6

Therapeutic Focus

Moderate or Severe Submental Fullness Healthy Moderate to Severe Convexity of Submental Fat Safety Efficacy

Clinical Trials (18)

NCT02035267 Phase 3 COMPLETED

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Started: 1/1/2014

NCT02163902 Phase 3 COMPLETED

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Started: 12/1/2013

NCT02123134 Phase 3 COMPLETED

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Started: 4/1/2014

NCT01426373 Phase 3 COMPLETED

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Started: 8/1/2011

NCT02007434 Phase 3 COMPLETED

Patient Experience Study of Deoxycholic Acid Injection

Started: 12/1/2013

NCT01305577 Phase 3 COMPLETED

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Started: 12/1/2010

NCT01542034 Phase 3 COMPLETED

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Started: 2/1/2012

NCT01546142 Phase 3 COMPLETED

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Started: 3/1/2012

NCT01294644 Phase 3 COMPLETED

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Started: 1/1/2011

NCT02159729 Phase 2 COMPLETED

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Started: 2/1/2009

NCT00618618 Phase 2 COMPLETED

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Started: 4/1/2008

NCT01032889 Phase 2 COMPLETED

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Started: 12/1/2009

NCT01462786 Phase 1 COMPLETED

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

Started: 10/1/2011

NCT00618709 Phase 1 COMPLETED

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Started: 1/1/2008

NCT01706679 Phase 1 COMPLETED

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

Started: 10/1/2012

NCT01632917 Phase 1 COMPLETED

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Started: 6/1/2012

NCT01319916 Phase 1 COMPLETED

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

Started: 12/1/2010

NCT00835952 Phase 1 COMPLETED

ATX-101 Abdominoplasty

Started: 11/1/2008

Drug Candidates

Deoxycholic Acid ATX-101 (1 mg/cm^2) ATX-101 (2 mg/cm^2) ATX-101 (4 mg/cm^2) ATX-101 Deoxycholic acid injection Deoxycholic Acid Injection Lidocaine / Epinephrine ATX-101 (10 mg/ml) ATX-101 (20 mg/ml)
Activity Status: Inactive
Last Trial Started: 4/1/2014
Last Trial Ended: 8/1/2016
Trials (12 months): 0
Completed Trials: 18
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.